Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 13, 2009

Addrenex Obtains Early-Stage Narcolepsy Drug from SK Holdings

Addrenex Obtains Early-Stage Narcolepsy Drug from SK Holdings

Addrenex licenses narcolepsy drug from South Korean company

  • Addrenex Pharmaceuticals will obtain rights to ADX-N05 from SK Holdings, a South Korean company, to expand its pipeline of adrenergic-regulating drugs. ADX-N05 is being designed to treat narcolepsy and possibly other neurologic conditions.

    Phase II testing of ADX-N05 is expected to begin this year for narcolepsy. The company says future trials may be instituted for the use of the compound as an adjunct therapy for depression.ADNFCR-2184-ID-19167164-ADNFCR

    The compound joins three other products in clinical trials. Clonicel is in a Phase III program for ADHD and ADX415 is in a Phase II hypertension study and a Phase I trial for menopausal flushing. ADX415 is partnered with Sciele Pharma. Sympres has been submitted for approval in hypertension, and an extended release version of the drug is being investigated in Phase II study for the same indication .

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »